Lymphoma, Large B-Cell, Diffuse: Clinical Trials

18 trials for Lymphoma, Large B-Cell, Diffuse, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

18 terminated. 18 Phase 3, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	18	Terminated 18
Phase 2	3	Terminated 3

Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg - Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2 / Phase 3	Terminated	Nektar Therapeutics	15	2023-02-23	2026-10-16
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Polatuzumab Vedotin, Bendamustine, Rituximab - Diffuse, Large B-Cell, Lymphoma	Phase 3	Terminated	Hoffmann-La Roche	42	2020-07-10	2023-03-03
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) JHL1101, MabThera - Diffuse Large B-Cell Lymphoma	Phase 3	Terminated	JHL Biotech, Inc.	8	2018-11-13	2020-01-09
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma	Phase 3	Terminated	Pfizer	29	2016-12-16	2020-12-17
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma	Phase 2 / Phase 3	Terminated	TG Therapeutics, Inc.	710	2016-05-25	2022-07-21
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Terminated	City of Hope Medical Center	3	2015-01-01	2018-03-12
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy Zevalin, Y-90-Zevalin, Rituximab - Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma	Phase 3	Terminated	Spectrum Pharmaceuticals, Inc	79	2012-04-19	2021-12-16
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) Rituximab, Obinutuzumab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma	Phase 3	Terminated	Hoffmann-La Roche	1418	2011-07-26	2019-04-12
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy Inotuzumab ozogamicin, Rituximab, rituximab + gemcitabine - Lymphoma, Non-Hodgkin	Phase 3	Terminated	Pfizer	338	2011-04-04	2019-01-08
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. Zevalin - Lymphoma, Large Cell, Diffuse	Phase 3	Terminated	Spectrum Pharmaceuticals, Inc	68	2006-05-01	2022-01-19
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant moxifloxacin hydrochloride, Placebo - Breast Cancer, Chronic Myeloproliferative Disorders	Phase 3	Terminated	OHSU Knight Cancer Institute	240	2006-05-01	2017-05-09
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) mycophenolate mofetil, placebo - Cancer	Phase 3	Terminated	Martin, Paul	151	2004-05-01	2013-05-03
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma rituximab - Diffuse Large Cell Lymphoma	Phase 3	Terminated	Lymphoma Study Association	223	2003-12-01	2017-03-13
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma CHOP regimen, EPOCH regimen, cyclophosphamide - Lymphoma	Phase 2 / Phase 3	Terminated	European Organisation for Research and Treatment of Cancer - EORTC	3	2003-03-01	2012-09-24
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma Rituximab, Doxorubicin, Cyclophosphamide - Lymphoma, Large-Cell, Diffuse	Phase 3	Terminated	Lymphoma Study Association	138	2001-10-16	2018-08-23
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma filgrastim, rituximab, carboplatin - Lymphoma	Phase 3	Terminated	SWOG Cancer Research Network	7	2000-10-01	2013-04-10
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma ACVBP, ACE, rituximab - CD20-Positive Large B-Cell Lymphoma	Phase 3	Terminated	Lymphoma Study Association	430	1999-10-01	2005-09-15
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation cyclosporine, cyclosporine and methotrexate - Leukemia, Lymphoma	Phase 3	Terminated	Baxalta now part of Shire	105	1997-04-01	2021-05-06

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding